Skip to main content
Erschienen in: Calcified Tissue International 4/2005

01.10.2005 | Laboratory Investigations

Enhancement of Crude Bone Morphogenetic Protein-Induced New Bone Formation and Normalization of Endochondral Ossification by Bisphosphonate Treatment in Osteoprotegerin-Deficient Mice

verfasst von: M. Tabuchi, K. Miyazawa, M. Kimura, H. Maeda, T. Kawai, Y. Kameyama, S. Goto

Erschienen in: Calcified Tissue International | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Osteoprotegerin (OPG) is a novel secreted member of the tumor necrosis factor receptor family which plays a crucial role in negative regulation of osteoclastic bone resorption. We investigated both the quantity and quality of heterotopic new bone induced by crude bone morphogenetic protein (BMP) as a means of examining bone metabolism by bisphosphonate administration in OPG−/− mice. Four weeks after implantation of crude BMP, the volume of heterotopic new bone in OPG−/− mice without alendronate was significantly less than in wild-type (WT) mice. Alendronate treatment of OPG−/− mice resulted in enhancement of the volume of heterotopic new bone. Histological findings revealed that WT mice showed normal bone formation with persistent cartilage that was interspersed with islands of bone. In contrast, the cartilage was replaced by trabecular bone and bone marrow adipocytes in OPG−/− mice without alendronate. However, some cartilage was still present in OPG−/− mice with alendronate compared to those without alendronate. All bone formation-related parameters and bone resorption-related parameters were significantly lower in OPG−/− mice with alendronate than in those without alendronate. These findings suggest that in stimulated osteoclastogenesis without OPG, osteoinductive activity induced by crude BMP is inhibited and endochondral ossification induced by crude BMP is accelerated. On the other hand, alendronate treatment of OPG−/− mice caused osteoinductive activity induced by crude BMP to increase and endochondral ossification induced by crude BMP to be decelerated. In conclusion, inhibition of stimulated osteoclastogenesis results in the enhancement of new bone formation and normalization of endochondral ossification.
Literatur
1.
Zurück zum Zitat Suda T, Takahashi N, Martin TJ (1992) Modulation of osteoclast differentiation. Endocr Rev 13:66–80CrossRefPubMed Suda T, Takahashi N, Martin TJ (1992) Modulation of osteoclast differentiation. Endocr Rev 13:66–80CrossRefPubMed
3.
Zurück zum Zitat Ott SM (2002) Histomorphometric analysis of bone remodeling. In: Bilezikian JP, Raisz LG, Rodan GA (eds), Principles of bone biology. Academic Press, New York, pp 303–319 Ott SM (2002) Histomorphometric analysis of bone remodeling. In: Bilezikian JP, Raisz LG, Rodan GA (eds), Principles of bone biology. Academic Press, New York, pp 303–319
4.
Zurück zum Zitat Osier LK, Marks SC (1992) Osteopetrosis. In: Rifkin BR, Gay CV (eds), Biology and physiology of the osteoclasts. CRC Press, Boca Raton, pp 433–453 Osier LK, Marks SC (1992) Osteopetrosis. In: Rifkin BR, Gay CV (eds), Biology and physiology of the osteoclasts. CRC Press, Boca Raton, pp 433–453
5.
Zurück zum Zitat Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed
6.
Zurück zum Zitat Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602CrossRefPubMed Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602CrossRefPubMed
7.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
8.
Zurück zum Zitat Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337CrossRefPubMed Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337CrossRefPubMed
9.
Zurück zum Zitat Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12PubMed Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12PubMed
10.
Zurück zum Zitat Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMed Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMed
11.
Zurück zum Zitat Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615CrossRefPubMed Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615CrossRefPubMed
12.
Zurück zum Zitat Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med 347:175–184CrossRefPubMed Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S (2002) Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med 347:175–184CrossRefPubMed
13.
Zurück zum Zitat Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119–2127CrossRefPubMed Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119–2127CrossRefPubMed
14.
Zurück zum Zitat Gennari C, Nuti R, Agnusdei D, Camporeale A, Martini G (1994) Management of osteoporosis and Paget’s disease. An appraisal of the risks and benefits of drug treatment. Drug Saf 11:179–195PubMed Gennari C, Nuti R, Agnusdei D, Camporeale A, Martini G (1994) Management of osteoporosis and Paget’s disease. An appraisal of the risks and benefits of drug treatment. Drug Saf 11:179–195PubMed
15.
Zurück zum Zitat MacGowan JR, Pringle J, Morris VH, Stamp TC (2000) Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget’s disease. Skeletal Radiol 29:279–282CrossRefPubMed MacGowan JR, Pringle J, Morris VH, Stamp TC (2000) Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget’s disease. Skeletal Radiol 29:279–282CrossRefPubMed
16.
Zurück zum Zitat Urist MR, Huo YK, Brownell AG, Hohl WM, Buyske J, Lietze A, Tempst P, Hunkapiller M, DeLange RJ (1984) Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci USA 81:371–375PubMed Urist MR, Huo YK, Brownell AG, Hohl WM, Buyske J, Lietze A, Tempst P, Hunkapiller M, DeLange RJ (1984) Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci USA 81:371–375PubMed
17.
Zurück zum Zitat Urist MR, Iwata H (1973) Preservation and biodegradation of the morphogenetic property of bone matrix. J Theor Biol 38:155–167CrossRefPubMed Urist MR, Iwata H (1973) Preservation and biodegradation of the morphogenetic property of bone matrix. J Theor Biol 38:155–167CrossRefPubMed
18.
Zurück zum Zitat Izawa H, Hachiya Y, Kawai T, Muramatsu K, Narita Y, Ban N, Yoshizawa H (2001) The effect of heat-treated human bone morphogenetic protein on clinical implantation. Clin Orthop 390:252–258PubMed Izawa H, Hachiya Y, Kawai T, Muramatsu K, Narita Y, Ban N, Yoshizawa H (2001) The effect of heat-treated human bone morphogenetic protein on clinical implantation. Clin Orthop 390:252–258PubMed
19.
Zurück zum Zitat Miyazawa K, Kawai T, Urist MR (1996) Bone morphogenetic protein-induced heterotopic bone in osteopetrosis. Clin Orthop 324:259–268CrossRefPubMed Miyazawa K, Kawai T, Urist MR (1996) Bone morphogenetic protein-induced heterotopic bone in osteopetrosis. Clin Orthop 324:259–268CrossRefPubMed
20.
Zurück zum Zitat Miyazawa K, Urist MR (1997) Treatment with recombinant human macrophage colony-stimulating factor resorbs blood clot and restores osteoclastogenesis in heterotopic bone induced by partially purified native bone morphogenetic protein in osteopetrotic (op/op) mice. J Orthop Res 15:456–462CrossRefPubMed Miyazawa K, Urist MR (1997) Treatment with recombinant human macrophage colony-stimulating factor resorbs blood clot and restores osteoclastogenesis in heterotopic bone induced by partially purified native bone morphogenetic protein in osteopetrotic (op/op) mice. J Orthop Res 15:456–462CrossRefPubMed
21.
Zurück zum Zitat Kimmel DB, Jee WSS (1983) Measurements of area, perimeter, and distance: details of data collection in bone histomorphometry. In: Recker RR (ed), Bone histomorphometry. Techniques and interpretation. CRC Press, Boca Raton, pp 89–108 Kimmel DB, Jee WSS (1983) Measurements of area, perimeter, and distance: details of data collection in bone histomorphometry. In: Recker RR (ed), Bone histomorphometry. Techniques and interpretation. CRC Press, Boca Raton, pp 89–108
22.
Zurück zum Zitat Janckila AJ, Li CY, Lam KW, Yam LT (1978) The cytochemistry of tartrate-resistant acid phosphatase. Technical considerations. Am J Clin Pathol 70:45–55PubMed Janckila AJ, Li CY, Lam KW, Yam LT (1978) The cytochemistry of tartrate-resistant acid phosphatase. Technical considerations. Am J Clin Pathol 70:45–55PubMed
23.
Zurück zum Zitat Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449CrossRefPubMed Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449CrossRefPubMed
24.
Zurück zum Zitat Cundy T, Wheadon L, King A (2004) Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 19:703–711PubMed Cundy T, Wheadon L, King A (2004) Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 19:703–711PubMed
25.
Zurück zum Zitat Reddi AH (1981) Cell biology and biochemistry of endochondral bone development. Coll Relat Res 1:209–226PubMed Reddi AH (1981) Cell biology and biochemistry of endochondral bone development. Coll Relat Res 1:209–226PubMed
26.
Zurück zum Zitat Urist MR, Hernandez A (1974) Excitation transfer in bone. Deleterious effects of cobalt 60 radiation-sterilization of bank bone. Arch Surg 109:586–593PubMed Urist MR, Hernandez A (1974) Excitation transfer in bone. Deleterious effects of cobalt 60 radiation-sterilization of bank bone. Arch Surg 109:586–593PubMed
27.
Zurück zum Zitat Urist MR, Silverman BF, Buring K, Dubuc FL, Rosenberg JM (1967) The bone induction principle. Clin Orthop 53:243–283PubMed Urist MR, Silverman BF, Buring K, Dubuc FL, Rosenberg JM (1967) The bone induction principle. Clin Orthop 53:243–283PubMed
28.
Zurück zum Zitat Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242:1528–1534PubMed Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242:1528–1534PubMed
29.
Zurück zum Zitat Luyten FP, Cunningham NS, Ma S, Muthukumaran N, Hammonds RG, Nevins WB, Woods WI, Reddi AH (1989) Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 264:13377–13380PubMed Luyten FP, Cunningham NS, Ma S, Muthukumaran N, Hammonds RG, Nevins WB, Woods WI, Reddi AH (1989) Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation. J Biol Chem 264:13377–13380PubMed
30.
Zurück zum Zitat Yoshikawa H, Nakase T, Myoui A, Ueda T (2004) Bone morphogenetic proteins in bone tumors. J Orthop Sci 9:334–340CrossRefPubMed Yoshikawa H, Nakase T, Myoui A, Ueda T (2004) Bone morphogenetic proteins in bone tumors. J Orthop Sci 9:334–340CrossRefPubMed
31.
Zurück zum Zitat Wozney JM (1992) The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32:160–167CrossRefPubMed Wozney JM (1992) The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32:160–167CrossRefPubMed
32.
Zurück zum Zitat Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342–349PubMed Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342–349PubMed
34.
Zurück zum Zitat Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105–4115CrossRefPubMed Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105–4115CrossRefPubMed
Metadaten
Titel
Enhancement of Crude Bone Morphogenetic Protein-Induced New Bone Formation and Normalization of Endochondral Ossification by Bisphosphonate Treatment in Osteoprotegerin-Deficient Mice
verfasst von
M. Tabuchi
K. Miyazawa
M. Kimura
H. Maeda
T. Kawai
Y. Kameyama
S. Goto
Publikationsdatum
01.10.2005
Erschienen in
Calcified Tissue International / Ausgabe 4/2005
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-004-0223-9

Weitere Artikel der Ausgabe 4/2005

Calcified Tissue International 4/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.